ABSTRACT:
The pharmacological management of diabetes mellitus has transitioned from a glucose-centric approach to a comprehensive strategy emphasizing cardiovascular and renal protection alongside weight regulation. This abstract reviews the current therapeutic landscape, dominated by the established efficacy of SGLT2 inhibitors and GLP-1 receptor agonists, and introduces the next generation of "incretin-based" multi-agonists. A significant focus is placed on tirzepatide (a dual GIP/GLP-1 receptor agonist) and the emerging triple-hormone agonists (targeting GLP-1, GIP, and glucagon receptors), which have demonstrated unprecedented levels of glycemic control and weight reduction in clinical trials. Furthermore, the 2026 therapeutic pipeline highlights the move toward once-weekly basal insulins and the FDA-approved use of teplizumab for the delay of Type 1 Diabetes progression. Additionally, the role of non-steroidal mineralocorticoid receptor antagonists (MRAs) like finerenone is examined for their specific benefits in mitigating diabetic kidney disease. This review underscores the importance of precision medicine—using AI-driven tools to predict individual drug responses—to optimize therapy, minimize adverse effects such as hypoglycemia, and reduce the global burden of diabetes-related complications.